CNS Market
Central Nervous System (CNS) Market Research , Intelligence and Forescasts
In this section you will find information products, including market research, covering Central Nervous System research, including latest technologies, company profiles, biopharmaceuticals, market data and information covering Europe, the UK, North America and Asia.
Stay up-to-date with new products added to this category »
| Title | Publication Date | Price |
|---|---|---|
| Multiple Sclerosis Drug Discoveries What the future holds |
January 2012 | £1295 |
| Antipsychotics Market to 2017 Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules |
January 2012 | £2215 |
| Addiction Control Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Insomnia Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Epilepsy Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Brain Hemorrhage Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
November 2011 | £2215 |
| Asperger Syndrome Global Clinical Trials Review H2, 2011 |
November 2011 | £630 |
| Cerebral Hypoxia Global Clinical Trials Review H2, 2011 |
November 2011 | £630 |
| Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
November 2011 | £2215 |
| Hemiplegia Global Clinical Trials Review H2, 2011 |
November 2011 | £630 |
| The Seventh International Congress on Vascular Dementia Post Conference Review and Analysis |
November 2011 | £630 |
| Renal Pain Global Clinical Trials Review H2, 2011 |
November 2011 | £630 |
| Paralysis Global Clinical Trials Review H2, 2011 |
November 2011 | £630 |
| Sleep Disorders Global Clinical Trials Review H2, 2011 |
November 2011 | £630 |
| Joint Pain Global Clinical Trials Review H2, 2011 |
November 2011 | £630 |
| Major Depressive Disorder (MDD) Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
October 2011 | £2215 |
| Dyskinesia - Pipeline Review H2 2011 |
October 2011 | £315 |
| Musculoskeletal Pain - Pipeline Review H2 2011 |
October 2011 | £315 |
| Fatigue - Pipeline Review H2 2011 |
October 2011 | £315 |
| Opium Addiction - Pipeline Review H2 2011 |
October 2011 | £315 |
| Cancer Pain - Pipeline Review H2 2011 |
October 2011 | £315 |
| Spasticity - Pipeline Review H2 2011 |
October 2011 | £315 |
| Anorexia Nervosa - Pipeline Review H2 2011 |
October 2011 | £315 |
| Psychosis - Pipeline Review H2 2011 |
October 2011 | £315 |
| Friedreich Ataxia - Pipeline Review H2 2011 |
October 2011 | £315 |
| Fracture - Pipeline Review H2 2011 |
October 2011 | £315 |
| Back Pain - Pipeline Review H2 2011 |
October 2011 | £315 |
| Dystonia - Pipeline Review H2 2011 |
October 2011 | £315 |
| Postherpetic Neuralgia - Pipeline Review H2 2011 |
October 2011 | £315 |
| Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review H2 2011 |
October 2011 | £315 |
